169 related articles for article (PubMed ID: 31475945)
1. Successful management of tertiary hyperparathyroidism associated with hypophosphataemic rickets in an adult.
Anagnostis P; Vamvakidis K; Tournis S
J Musculoskelet Neuronal Interact; 2019 Sep; 19(3):370-373. PubMed ID: 31475945
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review.
Yavropoulou MP; Kotsa K; Gotzamani Psarrakou A; Papazisi A; Tranga T; Ventis S; Yovos JG
Hormones (Athens); 2010; 9(3):274-8. PubMed ID: 20688626
[TBL] [Abstract][Full Text] [Related]
3. Parathyroidectomy versus Cinacalcet in the Management of Tertiary Hyperparathyroidism: Surgery Improves Renal Transplant Allograft Survival.
Finnerty BM; Chan TW; Jones G; Khader T; Moore M; Gray KD; Beninato T; Watkins AC; Zarnegar R; Fahey TJ
Surgery; 2019 Jan; 165(1):129-134. PubMed ID: 30415867
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet treatment experience in hereditary vitamin D resistant rickets.
Lucas J; Badia JL; Lucas E; Remon A
J Pediatr Endocrinol Metab; 2020 Feb; 33(2):313-318. PubMed ID: 31926093
[TBL] [Abstract][Full Text] [Related]
5. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet.
Raeder H; Shaw N; Netelenbos C; Bjerknes R
Eur J Endocrinol; 2008 Dec; 159 Suppl 1():S101-5. PubMed ID: 18775977
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hypophosphataemic rickets in children remains a challenge.
Nielsen LH; Rahbek ET; Beck-Nielsen SS; Christesen HT
Dan Med J; 2014 Jul; 61(7):A4874. PubMed ID: 25123121
[TBL] [Abstract][Full Text] [Related]
7. Effects of Long-Term Cinacalcet Administration on Parathyroid Gland in Hemodialysis Patients with Secondary Hyperparathyroidism.
Okuno S; Inaba M; Ishimura E; Nakatani S; Chou H; Shoji S; Yamakawa T
Nephron; 2019; 142(2):106-113. PubMed ID: 30712039
[TBL] [Abstract][Full Text] [Related]
8. Therapy for persistent hypercalcemic hyperparathyroidism post-renal transplant: cinacalcet versus parathyroidectomy.
Rivelli GG; Lima ML; Mazzali M
J Bras Nefrol; 2020; 42(3):315-322. PubMed ID: 32720971
[TBL] [Abstract][Full Text] [Related]
9. Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients.
DeLacey S; Liu Z; Broyles A; El-Azab SA; Guandique CF; James BC; Imel EA
Bone; 2019 Oct; 127():386-392. PubMed ID: 31276850
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of parathyroidectomy versus cinacalcet in the clinical management of secondary hyperparathyroidism.
Kim WW; Rhee Y; Kim BS; Kim K; Lee CR; Kang SW; Lee J; Jeong JJ; Nam KH; Chung WY
Endocr J; 2019 Oct; 66(10):881-889. PubMed ID: 31189770
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of a randomized study comparing parathyroidectomy with cinacalcet for treating tertiary hyperparathyroidism.
Moreno P; Coloma A; Torregrosa JV; Montero N; Francos J; Codina S; Manonelles A; Bestard O; García-Barrasa A; Melilli E; Cruzado JM
Clin Transplant; 2020 Aug; 34(8):e13988. PubMed ID: 32438479
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
[TBL] [Abstract][Full Text] [Related]
13. X-linked hypophosphataemic rickets: Report of a novel PHEX mutation and cinacalcet as adjuvant therapy in the mineral metabolism control.
Cavaco D; Amaro P; Simões-Pereira J; Pereira MC
Mod Rheumatol Case Rep; 2022 Jan; 6(1):145-149. PubMed ID: 34561702
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet therapy in an infant with an R185Q calcium-sensing receptor mutation causing hyperparathyroidism: a case report and review of the literature.
Forman TE; Niemi AK; Prahalad P; Shi RZ; Nally LM
J Pediatr Endocrinol Metab; 2019 Mar; 32(3):305-310. PubMed ID: 30730839
[TBL] [Abstract][Full Text] [Related]
15. Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism.
Kuczera P; Adamczak M; Machnik G; Okopien B; Wiecek A
Nephron; 2018; 139(4):286-292. PubMed ID: 29879701
[TBL] [Abstract][Full Text] [Related]
16. Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid Adenoma.
Florakis D; Karakozis S; Tseleni-Balafouta S; Makras P
J Musculoskelet Neuronal Interact; 2019 Sep; 19(3):379-384. PubMed ID: 31475947
[TBL] [Abstract][Full Text] [Related]
17. Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients.
Xipell M; Montagud-Marrahi E; Rubio MV; Ojeda R; Arias-Guillén M; Fontseré N; Rodas L; Vera M; Broseta JJ; Torregrosa V; Filella X; Maduell F
Blood Purif; 2019; 48(2):106-114. PubMed ID: 30699421
[TBL] [Abstract][Full Text] [Related]
18. Parathyroidectomy for tertiary hyperparathyroidism associated with X-linked dominant hypophosphatemic rickets.
Savio RM; Gosnell JE; Posen S; Reeve TS; Delbridge LW
Arch Surg; 2004 Feb; 139(2):218-22. PubMed ID: 14769584
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in patients with renal hyperparathyroidism requiring cinacalcet pre-operatively followed by parathyroidectomy.
Baker D; Sevak S; Callahan RE; Czako PF; Lloyd LR; Nagar S
Am J Surg; 2019 Jan; 217(1):146-151. PubMed ID: 29929906
[TBL] [Abstract][Full Text] [Related]
20. Preoperative calcitriol reduces postoperative intravenous calcium requirements and length of stay in parathyroidectomy for renal-origin hyperparathyroidism.
Alsafran S; Sherman SK; Dahdaleh FS; Ruhle B; Mercier F; Kaplan EL; Angelos P; Grogan RH
Surgery; 2019 Jan; 165(1):151-157. PubMed ID: 30413326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
